Global Dengue Treatment Market, By Strains (DENV-1, DENV-2, DENV-3, DENV-4, Others), Transmission (Mosquito-to-Human Transmission and Mother-to-Child Transmission), Type (Medication, Supportive Care, Vaccination and Others), Severity (Uncomplicated and Severe), Route of Administration (Oral and Parenteral), Mode of Purchase (Prescription and Over the Counter (OTC)), End-User (Hospitals, Specialty Clinics, Home Healthcare, and Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Others) – Industry Trends and Forecast to 2031.
Dengue Treatment Market Analysis and Size
The dengue treatment market is majorly used in the development and distribution of antiviral drugs and vaccines to combat dengue fever. The market focuses on research, innovation, and collaboration to address the increasing incidence of dengue, aiming to reduce the severity of the disease, minimize complications, and ultimately contribute to global public health.
Data Bridge Market Research analyses the global dengue treatment market, which was USD 747.85 million in 2023, is expected to reach USD 1,178.53 million by 2031, at a CAGR of 5.85% during the forecast period 2024 to 2031. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2024-2031
|
|
Base Year
|
2023
|
|
Historic Years
|
2022 (Customizable to 2016-2021)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Strains (DENV-1, DENV-2, DENV-3, DENV-4, Others), Transmission (Mosquito-to-Human Transmission and Mother-to-Child Transmission), Type (Medication, Supportive Care, Vaccination and Others), Severity (Uncomplicated and Severe), Route of Administration (Oral and Parenteral), Mode of Purchase (Prescription and Over the Counter (OTC)), End-User (Hospitals, Specialty Clinics, Home Healthcare, and Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Others)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Pfizer Inc. (U.S.), Perrigo Company plc (Ireland), GSK plc (U.K.), Dr. Reddy’s Laboratories Ltd. (India), Fresenius Kabi USA, (U.S.), Sun Pharmaceutical Industries Ltd. (India), Abivax (France), Aurobindo Pharma (India), Baxter (U.S.), EMERGEX VACCINES (U.S.), Hikma Pharmaceuticals PLC (U.K.), Sanofi (France), Takeda Pharmaceutical Company Limited (Japan)
|
|
Market Opportunities
|
|
Market Definition
Dengue, a swiftly spreading viral disease, has proliferated across all world health organization (WHO) regions in recent times. The primary culprits in transmitting the dengue virus are female mosquitoes, predominantly from the Aedes aegypti genus and to a lesser extent from Ae. albopictus. These vectors also play a role in transmitting other diseases such as chikungunya, yellow fever, and Zika viruses. The global spread of these mosquito-borne illnesses underscores the significance of comprehensive preventive measures and heightened awareness campaigns.
Global Dengue Treatment Market Dynamics
Drivers
- Rising Dengue Incidence Increases the Demand for Effective Treatment Options
As the number of dengue infections continues to rise, there is an increasing demand for effective treatment options to address the immediate health concerns associated with the disease. This surge in demand propels pharmaceutical companies and healthcare providers to invest in research, development, and deployment of innovative treatments, creating a fertile ground for market expansion and the introduction of new therapeutic solutions to combat the rising dengue burden.
- Advancements in Drug Development Enhances the Treatment
Ongoing advancements in drug development and the introduction of novel antiviral drugs and therapies are propelling the global dengue treatment market. Pharmaceutical companies are investing in research to discover and develop more efficacious and targeted treatments for dengue, leading to a pipeline of innovative drugs. This enhances the treatment landscape and fosters market growth by offering improved therapeutic options for patients.
Opportunities
- Pharmaceutical Industry Collaboration Drives Discovery of Highly Effective Treatments
The collaborative efforts within the pharmaceutical industry present a pivotal opportunity for the global dengue treatment market. This collaborative approach accelerates the discovery and development of highly effective treatments for dengue by fostering partnerships and shared research endeavors. Such synergies can lead to innovative therapeutic solutions, ensuring a more robust arsenal against the disease. This collaborative spirit enhances the efficiency of research and contributes to the overall advancement of dengue treatment options, promising improved patient outcomes and a strengthened position for the global market in combating this public health challenge.
- Public Health Initiatives Contributes in Disease Management
Joint efforts in implementing comprehensive public health initiatives, including vector control programs, education campaigns, and affordable treatment access, can create a more conducive environment for combating dengue. Collaborative approaches can address the treatment aspect and contribute to prevention and disease management, potentially opening up avenues for sustainable business models and partnerships.
Restraints/Challenges
- Limited Accessibility to Healthcare Services in Remote Areas
The challenges of reaching and providing medical care in isolated regions hinder the effective distribution of dengue treatment interventions, impacting the market's growth. In remote areas, the lack of proper infrastructure, healthcare facilities, and skilled professionals further exacerbates the difficulty in managing and treating dengue cases, impeding the market's reach and effectiveness.
- High Development Costs Limits the Cost-Effective Solutions
The expenses associated with research, clinical trials, and regulatory approvals for dengue treatments contribute to the overall financial burden. These high development costs can impede the development and accessibility of affordable and efficient treatments for dengue, hindering the market's ability to provide cost-effective solutions to a wider population.
This global dengue treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global dengue treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Recent Developments
- In May 2022, Mylab Discovery Solutions launched a comprehensive RT-PCR test kit capable of detecting Sars-CoV-2 and various monsoon diseases, including malaria, Chikungunya, dengue, Zika, Leptospirosis, Salmonellosis, and Leishmaniasis, showcasing a versatile diagnostic approach
- In May 2022, Anitoa System launched a portable RT-PCR molecular test specifically designed for detecting dengue virus infections, providing a convenient and efficient tool for quick and accurate diagnosis in various settings
- In December 2021, Kao Corporation initiated a campaign to combat the spread of dengue fever, utilizing its proprietary technology to develop products for the cause. The campaign involved the distribution of 80,000 units and a donation of 6.5 Million Thai baht to the Thai Ministry of Public Health, contributing to both awareness and practical solutions for Dengue disease
- In March 2021, Takeda Pharmaceutical received approval from the Europe Medicines Agency (EMA) for its TAK-003 dengue vaccine candidate, targeted at preventing outbreaks in individuals aged 4 to 60. The company planned subsequent regulatory applications in several countries, underscoring advancements in dengue prevention through vaccination
Global Dengue Treatment Market Scope
The global dengue treatment market is segmented on the basis of strains, transmission, type, severity, route of administration, mode of purchase, end-user and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Strains
- DENV-1
- DENV-2
- DENV-3
- DENV-4
- Others
Transmission
- Mosquito-to-Human Transmission
- Mother-to-Child Transmission
Type
- Medication
- Supportive Care
- Vaccination
- Others
Severity
- Uncomplicated
- Severe
Route of administration
- Oral
- Parenteral
Mode of Purchase
- Prescription
- Over the Counter (OTC)
End-User
- Hospitals
- Specialty Clinics
- Home Healthcare
- Others
Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Others
Global Dengue Treatment Market Regional Analysis/Insights
The global dengue treatment market is analysed and market size insights and trends are provided by strains, transmission, type, severity, route of administration, mode of purchase, end-user and distribution channel as referenced above.
The countries covered in the global dengue treatment market report are U.S., Canada, Mexico, Germany, France, U.K., Italy, Spain, Russia, Poland, Turkey, Switzerland, Netherlands, Belgium, Hungary, Austria, Norway, Ireland, Lithuania, rest of Europe, China, Japan, India, Australia, South Korea, Singapore, Thailand, Malaysia, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Brazil, Argentina, Peru, Rest of South America, South Africa, Saudi Arabia, U.A.E., Israel, Egypt, Kuwait and Rest of Middle East and Africa.
North America dominates in the market due to its substantial consumer market and high GDP, fostering a conducive environment for industry growth. The region's emphasis on expanding research and development activities, coupled with a trend towards outsourcing services, further solidifies its leadership position in driving advancements and innovation within the sector.
The Asia-Pacific is expected to grow with the highest CAGR in the forecasted period, driven by rapidly increasing demand for dengue treatment products. This surge is attributed to the combined factors of urbanization and laboratory automation. Within the region, China is anticipated to lead the dengue treatment market, displaying its prominence in adopting and influencing developments in this healthcare sector.
Europe is expected to experience significant growth with a CAGR in the forecasted period, attributed to increasing research and development (R&D) endeavors within the pharmaceutical and biotech sectors. Germany is anticipated to emerge as a dominant force in the Europe market, reflecting its robust contributions to innovation and advancements in these industries.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure Growth Installed base and New Technology Penetration
The global dengue treatment market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for global dengue treatment market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the global dengue treatment market. The data is available for historic period 2016-2021.
Competitive Landscape and Global Dengue Treatment Market Share Analysis
The global dengue treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the company’s focus related to global dengue treatment market.
Some of the major players operating in the global dengue treatment market are:
- Pfizer Inc. (U.S.)
- Perrigo Company plc (Ireland)
- GSK plc (U.K.),
- Dr. Reddy’s Laboratories Ltd. (India)
- Fresenius Kabi USA, (U.S.)
- Sun Pharmaceutical Industries Ltd. (India)
- Abivax (France)
- Aurobindo Pharma (India)
- Baxter (U.S.)
- EMERGEX VACCINES (U.S.)
- Hikma Pharmaceuticals PLC (U.K.)
- Sanofi (France)
- Takeda Pharmaceutical Company Limited (Japan)
SKU-